

Index

Page numbers in *italics* refer to illustrations; those in **bold** refer to tables.

14-3-3 proteins 70–71, 174, 245

A

abducens palsy 194

A β peptides

A β_{1-40} 70, 170

A β_{1-42} 70, 170, 237, 245, **257**

in Lewy body dementia 170

see also β -amyloid

abetalipoproteinemia 85

ABGA see anti-basal ganglia antibodies

absolute values, interlaboratory CSF survey 251

Acanthamoeba spp. **226**

ACE see angiotensin-converting enzyme

acetylcholine receptor (AChR), autoantibodies 144, 145

acetylcholine receptor (AChR) antibodies, detecting 87

acid phosphatase, staining 110

acridinium ester, in chemiluminescence assay 22

activator protein deficiency 222

acute demyelinating encephalomyelitis 141

acute hemorrhagic leukoencephalitis 141

acute motor and sensory axonal neuropathy (AMSAN) 151

acute motoraxonal neuropathy (AMAN) 151

acute-phase proteins 73, **159**

adenocarcinoma, leptomeningeal metastasis 203, **204**

adrenoleukodystrophy, and neuropathy 191

AECA see antibodies against endothelial cells

African sleeping sickness see trypanosomiasis

agarose gel 25, 26–28

age-related variations

in CSF flow 9

see also references ranges, age-related

agglutination methods 18

AGNA see anti-SOX1

agricultural workers, Whipple's disease 137

AIDS dementia 91

AIDS patients

HIV antibody index 127

see also HIV; immunosuppressed patients

alanine, increased plasma levels 212

albumin

concentration gradient in CSF 5

detection methods 45

as marker protein in CSF 45

albumin quotient (Q_{Alb})

age-related changes 4, 250

age-related reference ranges 9, 238, 254, **256, 257**

and blood-CSF barrier function 45

in Guillain-Barré syndrome 149

in multiple sclerosis 138

as reference for serum proteins in CSF 45

albuminocytological dissociation, in Guillain-Barré syndrome 149–150

alcohol markers 77–78, 176

alkaline phosphatase 21, 38

placental (PLAP) 201

allelic heterogeneity 100, 103, 104

alphafetoprotein (AFP) 201

Alzheimer's disease 69, 70, 166–170

genetic factors 104

AMAN see acute motoraxonal neuropathy

amebic meningitis 117, 118

amino acids

blood-brain barrier 5

reference ranges 254, **258**

amphiphysin, antibodies 143

ampholytes 25

see also carrier ampholytes

AMSAN see acute motor and sensory axonal neuropathy

amyloid, Congo red stain 110

β -amyloid, in myositis 147

amyloid, in nerve biopsy 193

β -amyloid peptides, in Alzheimer's disease 70, 166, 169–170, 170, 177

amyloid plaques, in Alzheimer's disease 70

amyloid precursor protein (APP) 70, **105**

gene 166

amyloidosis

in Alzheimer's disease and CJD 70

familial 192

ANA see antinuclear antibodies

analytical comments, reporting 246–248

ANCA see anti-neutrophil cytoplasmic antibodies

Angiostrongylus cantonensis **227**, 228–229, 230

angiotensin-converting enzyme (ACE) 75–76

elevated in systemic sarcoidosis 142

ANNA-3 antibodies 93, **94**

anti-basal ganglia antibodies (ABGA) 92

anti-CRMP-5/CV2 93, **94**, 95, 96

anti-dsDNA 88

anti-glia nuclear antibodies (AGNA) see anti-SOX1

anti-GluR1 antibodies 163

anti-Hu antibodies 93, **94**, 95, 96, 162, 163

anti-neutrophil cytoplasmic antibodies

(ANCA) 87, 89–90, 156

atypical (aANCA) 90

reference ranges 90

in systemic vasculitis 190

see also cytoplasmic ANCA; perinuclear ANCA

anti-NMDA receptor antibodies 93

anti-Ri antibodies 93, **94**, 163

anti-SOX1 (AGNA) 93, **94**, 145, **161**, **162**, 163

anti-Yo antibodies 93, **94**, 95, 162, 163

antibodies

against endothelial cells (AECAs) 156

antigen binding sites 18

concentration 17

detection 68

fluorescent-labeled 38

in immunocytochemistry **38**

interlaboratory CSF survey 252

intrathecal see intrathecal antibodies; intrathecal immunoglobulin

nomenclature 46

persistence 132

specific 239, 252

specificity and affinity 18

steric hindrance 18

synthesis, intensity 242

valency 18

antibody index (AI)

comparative sensitivity 55

definition 54

in detection of bacterial and viral infections 68

in inflammatory neurological diseases **244**

interpretation **55**

for intrathecal synthesis 96

vs specific antibody fraction **244**

antibody-coated latex particles 21, 61

anticipation 103

anticoagulation treatment 179

anticonvulsants

therapeutic drug monitoring 81

therapeutic ranges **82**

antidepressants, therapeutic drug monitoring 81

antigen excess, causes false low values in nephelometry 21

antigen-antibody binding 17–18

antigen-antibody complex

analytical methods 18–23

formation 17, 18

quantitative detection 17

size 21

solubility 21

antigen-driven immunoblot 29

antigens

commercially available 132

concentration 17

recombinant 25, 89, 96, 97, 130, 132, 162

antineuronal antibodies 91–97, 157, 160–161

detection 93

diagnostic value 91

target antigens **162**

antinuclear antibodies (ANA)

analysis 88–89

in connective tissue diseases 156, 190

detection 87, 88

in multiple sclerosis 140

reference range 89

antisera, used for protein determination 18

- aortic arch arteritis *see* Takayasu's syndrome
- ApoE e4 allele, in Lewy body dementia 170
- ApoE gene **105**, 166, **168**, 169, 170
- apoE receptors 79
- aquaporin-4 87, 141
- antibodies 87, 157
- arsenic
- intoxication 191–192
 - reference values **192**
- arteriopathies, genetically determined 181
- arthropod bite, skin biopsy 118
- arylsulfatase A activity 222
- aspartylglucosaminuria 216, **217**
- aspergillosis 130
- Aspergillus*, pathogenic species 130
- Aspergillus fumigatus*, latex agglutination test 63
- aspiration, CT-guided, of spinal epidural abscess 122
- association rate constant 17
- astrocytes, response to insult 56
- ataxia
- autoimmune-mediated 144
 - see also* Friedrich's ataxia; gluten ataxia; spinocerebellar ataxia
- atherosclerosis 78–79, 80
- atomic absorption spectrophotometry 191, 192
- autoantibodies 86–91
- acetylcholine receptor (AChR) 144, 145
 - associated diseases **86**, **158**
 - calcium channels 91, 145
 - in connective tissue diseases **158**
 - detection 87, 88
 - ganglioside 151, 152, 188
 - glutamic acid decarboxylase (GAD) 92–93, 144
 - in immune vasculitis **86**
 - in immune-mediated central nervous system disorders **87**
 - interferons 145
 - interpretation 91
 - motor end plate diseases **86**
 - MuSK 145
 - in myositis 146, **147**
 - ribosomal P protein 157
 - in systemic inflammation 86
- autoimmune diseases 138–165
- demyelinating 136
 - ESR 75
 - and Hashimoto's thyroiditis 76
 - IL-6 levels 73
 - MRZ reaction 124, 139
 - neuromyelitis optica 141
 - oligoclonal IgG 139
 - polyendocrinopathy 92, 143, 144
 - post-streptococcal 92
 - stiff person syndrome 142, **143**
- autoimmune reactions, in immunosuppressed patients 126
- automated procedures
- in cerebrospinal fluid (CSF) analysis 21
 - in cytometry 36
 - in hematology 36
 - in nephelometry 46–47
 - sequence analysis 102
- avidity 17–18
- B**
- B cells *see* lymphocytes
- bacteria
- culture 64
 - gram-positive and gram-negative 61
 - microscopic detection 61, 62–63
 - rapid antigen testing 63
 - see also* individual genera/species
- bacterial endocarditis, CSF changes **120**
- bacterial infections 117–123
- immunodetection methods 55
- bacterial meningitis
- blood–CSF barrier dysfunction 9
 - clinical features 117
 - CSF collection 117
 - CSF glucose levels 58
 - CSF lactate levels 56, 58
 - CSF/serum quotients 9, **10**
 - diagnosis 117
 - eosinophilic granulocytes 41, 42
 - epidemiology and etiology 117
 - geographic differences 231
 - identification of pathogens 61
 - lumbar puncture 33
 - nonpurulent 119
 - nosocomial 117
 - pathogen detection 67, 118
 - pathogens **117**
 - PCR detection of microbial DNA 67
 - purulent 11
 - typical CSF findings 117–118
- bacterial nucleic acids, detection in CSF **67**
- Balamuthia mandrillaris* **226**
- Balo's concentric sclerosis 141
- basophilic granulocytes *see* granulocytes, basophilic
- Baylisascaris procyonis* **228**
- Becker muscular dystrophy *see* muscular dystrophies
- Beckman nephelometer 19
- Behçet's disease 155
- Bence Jones proteins 24, 88, 91, 188
- benign intracranial hypertension *see* pseudotumor cerebri
- Berlin blue reaction 38
- beta-trace protein 11, 12, 195, 196, 199, 245
- bilirubin 39
- Binswanger's disease *see* subcortical arteriosclerotic encephalopathy
- biochemical tissue analysis, pitfalls 216
- biopsy
- stereotactic methods 108
 - see also* brain biopsy; muscle biopsy; nerve biopsy; skin biopsy
- blindness 194
- blood analysis
- in neurological diseases 246
 - pitfalls 215
- blood contamination
- of cerebrospinal fluid (CSF) 40–41, 123, 130, 238, 255–256, **258**
 - correction 255–256
- blood cultures 64
- blood tests
- for drug detection 176
 - for lysosomal diseases 222
- blood–brain barrier
- damaged 80
 - dysfunction
 - in intracerebral hemorrhage 182
 - in ischemic stroke 181
 - local 4
 - in newborns 9
 - permeability 5, 13
 - structure 5
- blood–brain concentration gradient 13
- blood–CSF barrier dysfunction 9–11
- calculation 52
 - in chronic inflammatory demyelinating polyneuropathy 151
 - in Guillain–Barré syndrome 149
 - and leptomeningeal spread 204, 205
 - in lymphoma 206
 - in multiple sclerosis 138
 - in primary brain tumour 201
- blood–CSF barrier function
- biophysical model 6–7
 - normal 9
 - physiology 4, 5–8
 - quantitative measurement 45
 - selectivity 9
 - in subacute sclerosing panencephalitis 135
- blood-derived proteins 5, 6
- blotting techniques 25, 28, 29
- see also* Southern blot; western blot
- bone marrow, injury during lumbar puncture 40
- Borrelia
- antigen detection 26
 - in chronic meningitis 119
 - detection by DNA PCR 65
 - facial nerve palsies 239
 - pathogenic species 130
 - polyneuroradiculitis 190
 - protein components 130
 - specific antibody 48
- Borrelia burgdorferi* antigens, SDS gel electrophoresis 24
- borreliosis
- stages and syndromes 131
 - see also* neuroborreliosis
- brain abscess 121–122
- brain biopsy
- for diagnosis of aspergillosis 130
 - indications 108
 - often unnecessary 136
 - for primary central nervous system lymphomas 205
 - stereotactic 200, 228
- brain capillaries, morphological features 5, 6
- brain metastases *see* central nervous system, metastases
- brain proteins
- in blood 12–13
 - in CSF 11–12
 - dynamics 11–12
 - as marker proteins for cerebral dysfunctions 12, 245
 - reference ranges 254, **257**
 - source 11
- brain tissue, use 93
- brain tumors 200–208
- primary 200–202
 - secondary *see* central nervous system, metastases
 - serum analysis 202
- branched DNA (bdDNA) technology 66

- breast cancer
 intrathecal tumor markers 204, 245
 leptomeningeal infiltration 44, 202
 paraneoplasia 143, **161**
 signet-ring cell 40
 breath testing, for alcohol 176
 bronchoalveolar lavage 142
- C**
- C-reactive protein (CRP) 73, 74–75
 CADASIL 103, **107**, 181
 CAG repeats, in huntingtin gene 101, 103
 calcium channels, autoantibodies 91, 145
 Campylobacter jejuni
 chronic inflammatory demyelinating polyneuropathy (CIDP) 190
 Guillain–Barré syndrome 151
 Canavan’s disease 224
 cANCA *see* cytoplasmic ANCA
 cancer
 genetic syndromes **107**
see also brain tumors; breast cancer; lung cancer; individual types of cancer
 Candida
 microscopic detection 61
 pathogenic species 129
 candidiasis 129–130
 carbohydrate-deficient transferrin (CDT) 77–78, 176
 carcinoembryonic antigen (CEA)
 intrathecal release 245
 as tumor marker 204
 card agglutination test, for trypanosomiasis 229
 cardiolipin 90
 carotene 83
 carrier ampholyte, pH gradient 24, 25
 cartilage cells, in CSF 39–40
 catheter irritation 44
 CD4 count 126, 127
 increased in sarcoidosis 142
 CDT *see* carbohydrate-deficient transferrin (CDT)
 celiac disease 92
 cell concentration, for CSF cytology 37
 cell counts
 correction 123
 importance 35
 and lactate values 56–57
 manual and automated 36–37
 procedures 36
 reference ranges 255
 cell culture, of genetically manipulated cell lines 64
 cell sedimentation, slides 37
 central European encephalitis virus 124–125
 central nervous system
 bacterial infections 240, 241
 metabolite analysis 215
 metastases 4, 202–205
 paraneoplastic syndromes **160**
 vasculitis 198
 cerebellar syndromes, GAD autoantibodies 144
 cerebral abscess *see* brain abscess
 cerebral herniation, risk in acute bacterial meningitis 33
 cerebral hypoxia 185
 cerebral infarction
 CSF analysis 181
 etiology 179, **180**, 181
 ischemic 179–182
 laboratory analysis 179, **180**
 cerebral ischemia, lactate levels 58
 cerebral venous thrombosis 179
 cerebritis, definition 121
 cerebrospinal fluid (CSF)
 analysis *see* cerebrospinal fluid (CSF) analysis
 blood contamination 40–41, 123, 130, 238, 255–256, **258**
 brain proteins 11–12
 catchment area in brain parenchyma 4
 cell count and cytology 235
 collection
 for cytology 35
 from ventricular catheter 32
 from ventricular drain 195
 methods 117
 tubes 31
 color 32, 38–39
 concentrations, of molecules of different sizes 7
 cytology 35–44, 200–201, 203
 diagnostic vs statistical interpretation 51
 diffusion/flow model 7, 11
see also cerebrospinal fluid (CSF) flow
 dynamic equilibrium 6
 electrophoresis 23
 fibrin contamination 39
 fistula 195
 glucose concentration 58–59
 hemorrhagic *see* blood contamination
 immunoglobulin concentration 49
 leakage model 9, 10
 leakage through puncture site 33
 physiology 3
 postmortem serum concentration 6
 in primary brain tumors 200–201
 protein *see* cerebrospinal fluid (CSF) proteins
 rhinorrhea and otorrhea 195–196
 rostrocaudal concentration gradient 8, 254
 sample handling 59–60
 sample volumes 54–55
 sediments, staining techniques 37
 tumor cell detection 203
 visual assessment 38–39, 235
 volume 3
 cerebrospinal fluid (CSF) analysis
 automation problems 21
 clinical importance 3–4
 contraindications 181
 control material 251
 correction for blood contamination 255–256, **258**
 ELISA 21
 flow chart 235, 237
 grouped 51
 importance of blood–CSF barrier 5
 levels **237**
 procedure 235
 report 235–248
 cerebrospinal fluid (CSF) findings
 in Alzheimer’s disease 169
 in aspergillosis 129–130
 in bacterial endocarditis **120**
 in brain abscess 121
 in candidiasis 129–130
 in central European encephalitis virus infection 125
 in chronic inflammatory demyelinating polyneuropathy 151–152
 in Creutzfeldt–Jakob disease 174
 in cryptococcosis 128
 in cytomegalovirus infection 126
 in frontotemporal lobar degeneration 172
 in Guillain–Barré syndrome 149–150, **150**
 in helminthic central nervous system infections **227**
 in HIV infection 127
 in HSV infection 124
 in leptomeningeal spread 204
 in Lewy body dementia 170
 in lysosomal diseases 222
 in meningeal infiltration 206
 in multifocal motor neuropathy 152–153
 in multiple sclerosis 138–140
 in multiple system atrophy 173
 in neuroborreliosis 132
 in neuropathies 192
 in neurosarcoidosis 142
 in neurosyphilis 134–135
 in paraneoplastic neurological syndromes 159–160
 in progressive multifocal leukoencephalopathy 136
 in protozoal central nervous system infections **227**
 in psychiatric disease 178
 in spinal epidural abscess 122
 in stiff person syndrome 143
 in subacute sclerosing panencephalitis 135
 in subarachnoid hemorrhage 183–184
 in toxoplasmosis 128
 in tuberculous meningitis 120
 in varicella zoster virus infection 124
 in ventriculitis 122–123
 in West Nile Virus infection 125
 in Whipple’s disease 137
 cerebrospinal fluid (CSF) flow
 acute obstruction 194
 age-related variations 9
 anatomy and physiology 3–5
 diffusion 5
 rate 7, 9
 cerebrospinal fluid (CSF) interpretation, training 253
 cerebrospinal fluid (CSF) laboratory, quality assessment 249–253
 cerebrospinal fluid (CSF) proteins 44–56
 analysis 235–236, 249
 concentrations 6, 7
 detection methods 44–45
 internal quality control 250–253
 molecular size 6
 numerical evaluation of data 49
 quality aspects 249
 reference range for blood-derived proteins 51
 serum proteins 9–11
 cerebrospinal fluid (CSF) report
 components 235
 evaluation 238–246
 example 236

- integrated 235, 250
interpretation 246–248
- cerebrospinal fluid (CSF)/serum quotient diagrams 7, 8, 47, 48–51
for IgG (Q_{IgG}), as a function of Q_{Alb} 8
importance 45
interlaboratory CSF survey 251
method-independent 249–250
molecular-size-dependent changes 8
as reference value 249–250
see also albumin quotient (Q_{Alb})
- cerebrospinal pressure
false values 34–35
low 33
measurement 34–35
- cerebrospinal puncture 30–34
- cerebrotendinous xanthomatosis 223–224
- ceruloplasmin (Cp) 76, 224
- cervical puncture 30
- cestodes **227**
- Charcot–Marie–Tooth disease 100, 104, 192
- chemiluminescence assay 22
- chenodeoxycholic acid 223, 224
- chiral chromatography 81
- chitotriosidase 222
- cholesterol, serum analysis 79
- choroid plexus, CSF production 3
- chronic encephalomyelitis *see* multiple sclerosis
- chronic infections, of the nervous system 135–137
- chronic inflammatory demyelinating polyneuropathy (CIDP) 147, 151–152
- chronic meningitis 119–120
transition to encephalitis 135
- Churg–Strauss syndrome 90, 155, 156
- CMV *see* cytomegalovirus
- CNS *see* central nervous system
- coagulation factors, and increased risk of thrombosis 179
- coagulation markers, monitoring 179
- coagulation testing, in intracerebral hemorrhage 182, **183**
- coagulopathy, relative contraindication for lumbar puncture 31
- cobalamin *see* vitamin B₁₂
- coma, nontraumatic 179
- CoMed CSF statistics tool **51, 52**
- compulsive–obsessive disorder 92
- concentration gradient
blood–brain 13
blood–CSF 6, 9
local 5, 6, 7
nonlinear 6, 7
rostrocaudal 6, 8, 11, 254
- confidentiality, in molecular diagnostic testing 100
- Congo red stain 110
- connective tissue diseases 154–159
autoantibodies **86, 158**
immune complex-mediated forms 156
laboratory findings 156, **157**
and multiplex neuropathies 190
- consent *see* informed consent
- Coomassie blue 45
- copper
accumulation 76
metabolic disorders 224
- cortisol, serum analysis 202
- countercurrent electrophoresis 88
- counting chamber *see* Fuchs–Rosenthal counting chamber; Neubauer counting chamber
- cranial CT, for subarachnoid hemorrhage 183
- cranial MRI *see* MRI
- cranial nerve palsies, possible complication of lumbar puncture 33
- cranial neuritis, varicella zoster virus 124
- craniocerebral trauma 56
- creatine kinase (CK)
analysis 80
elevated 119
inflammatory myopathies 146
as marker of epileptic seizures 197
- Creutzfeldt–Jakob disease (CJD) 174–176
14–3–3 isoforms 71
diagnostic criteria **174, 176**
differential diagnosis 69
early diagnosis 166
familial **107**
genetic aspects 175
and Lewy body dementia 170
tau protein 69
- cross-reactivity 18, 55, 126
- cryoglobulinemic polyneuropathy 147, 153–154
- cryoglobulins 91, 153, **154, 156**
- cryptococcal meningitis 42
- cryptococci
microscopic detection 61
rapid antigen testing 63
- cryptococcosis 128–129
- Cryptococcus neoformans
culture 64
India ink preparation **129**
- culture, of genetically manipulated cell lines 64
- culture methods
for detection of mycobacteria 120
for propagation of pathogens 63–64
- cystatin C 11, 199
- cysticercosis 41
- Cysticercus cellulosae* **227**
- cytocentrifugation 37
- cytochrome C oxidase, staining 110
- cytokines, as indicators of inflammation 73
- cytology, in CSF analysis 35–44
- cytomegalovirus (CMV) 126
culture 64
detection by DNA PCR 65
encephalitis 122
infection, leading to Guillain–Barré syndrome 151
polyneuroradiculitis 190
- cytometric systems, automated 36
- cytopathic effect (CPE) 64
- cytoplasmic ANCA (cANCA) 89–90, 156
- cytostatic drugs, unable to reach CSF 202

D

- D-dimers, in subarachnoid hemorrhage 184
- Danon's disease 216, **217**
- dark-field microscopy 134
- dementia
AIDS-related 91
core symptoms **168**
definition 166

E

- E. coli
in bacterial meningitis 117
rapid antigen testing 63
- Echinococcus* spp. **227, 228**
- echinocytes 184

- EEG
 in Creutzfeldt–Jakob disease 174
 in subacute sclerosing panencephalitis 135–136
- electroimmunodiffusion 18, 19, 46
- electrolytes
 imbalances 119
 reference values **255**
- electromyography, of external sphincter muscle 173
- electron transport chain 211
 defects 212
- electrophoresis 23, 24
- electrophoresis gels, types 25
- electrophoretic methods
 blotting 25
 with immunodetection 26–27
 qualitative 23–29
- ELISA
 in autoantibody detection 87
 for cANCA and pANCA 90
 for IgA and IgM 46
 for neuroborreliosis 132
 for paraneoplastic antineuronal antibodies 97
 see also enzyme immunoassay
- Elsberg syndrome 124
- encephalitis
 and chronic meningitis 135
 hemorrhagic 124, 182
 herpes simplex virus (HSV) 239, 241, 242
 limbic 160, 198
 tick-borne 124
 viral 123
- endocrine markers 78
- Entamoeba histolytica* **226**
- enterococci, in shunt-associated ventriculitis 122
- enteroviruses, PCR detection 67
- enzymatic tests, for lactate 57
- enzyme histochemical staining, for muscle biopsy 110
- enzyme immunoassay 22
 for drug screening 176
- eosinophilia, associated with central nervous system parasitoses 228, 229
- eosinophilic granulocytes see granulocytes, eosinophilic
- ependymoma, risk of meningeal involvement 200
- epilepsy
 genetic factors 104
 importance of laboratory analysis 197
- epileptic seizures 197–199
- epithelial cells, in CSF 40
- epitopes 18
- Epstein–Barr virus (EBV)
 detection by PCR 65
 and Guillain–Barré syndrome 151
 induced B-cell activity 43
 in primary central nervous system lymphomas (PCNSL) 205
- equilibrium constant 17
- erythrocytes 40, 41
- erythroblasts see normoblasts
- erythrocyte sedimentation rate (ESR)
 in autoimmune diseases 73
 in cerebral infarction **179, 180**
 in dementia diagnosis **169**
 as inflammation marker 75
- in polyneuropathies 188
- in psychiatric diseases **176, 177, 178**
- in systemic diseases 155, **156, 157, 159**
- in temporal arteritis 180
- erythrophages 184, 185, 195
- ethylene oxide, allergic reaction 195
- evaluation, method-related vs patient-related 252–253
- exchange equilibrium 238
- exons 99
- external quality assurance (EQA) 249, 251
- extractable nuclear antigen (ENA) 89
- F**
- Fabry's disease 191, 216, **217**
- facial nerve palsy 54, 55, 132, 239
- facioscapulohumeral muscular dystrophy 109
- factor VIII concentration 179
- factor XIII 179
- familial frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) 172
- Farber's disease 216, **217**
- fasting glucose measurement 77
- fatty acid degradation, peroxisomal 222
- ferritin
 in subarachnoid hemorrhage 184
 supplementary test to cytology 245
- fibrin contamination in CSF 39
- beta-fibrinogen polymorphisms 179
- fibroblast culture 216, 222
- Fick's First Law 5
- Fick's Second Law 7
- filariform larvae, in subarachnoid space **228**
- filipin staining 222
- fixation methods, and staining behaviors 93
- flow chart, for CSF analysis 235, 237
- fluorescein isothiocyanate (FITC) 23
- fluorescence polarization immunoassays (FPIA), for drug screening 176
- fluorescence-activated cell sorting (FACS) 206
- fluorescent treponemal antibody absorption (FTA-Abs) 134
- fluorescence immunoassay 23
- alpha-fodrin antibodies 157
- folic acid 76–77
 deficiency 85
- foramen of Monro, as reference system 35
- foreign body reaction 41, 195
- Friedreich's ataxia 103
- frontotemporal lobar degeneration 171–172
- frozen sections, preparation 110
- fructosamine 77
- Fuchs' heterochromic iridocyclitis 241
- Fuchs–Rosenthal counting chamber 36
- fucosidosis 216, **217**
- fungal infections
 diagnosis 68
 of the nervous system 128–130
- fungal meningitis, lactate levels 58
- fungi
 culture 64
 microscopic detection 61
 rapid antigen testing 63
- G**
- gain-of-function mutation 99, 103
- galactomannan antigen 130
- galactosialidosis 216, **217**
- ganglionitis, varicella zoster virus 124
- ganglioside antibodies 153
- ganglioside autoantibodies 188
 in Guillain–Barré syndrome 151
 in multifocal motor neuropathy 152
- gangliosidosis 216, **218, 222**
- Gaucher's disease 216, **218, 222**
- GD1a antibodies 151
- GD1b antibodies 153
- GD3 antibodies 153
- gene products 99
- genes 99
- genetic counseling 100
- genetic heterogeneity 100
- genetic information, organization 99
- genetic predisposition to disease 100
- genome detection 66–67
- gephyrin antibodies 143
- gliadin antibodies 92
- glial cells, nuclear staining **94**
- glial fibrillary acidic protein (GFAP) 201
- glioblastoma, meningeal spread 200
- glucose
 in cerebrospinal fluid (CSF) 58–59
 determination 58–59, 77
 effect of serum levels 59
 fasting measurement 77
 impaired metabolism 59
 interlaboratory CSF survey 253
 inverse relationship with lactate 86
 monitoring 179
 reference ranges **59**
 transport through blood–brain barrier 58
- glutamate decarboxylase antibodies 143, 144
 autoantibodies 92–93
- gluten ataxia 92
- glycogenosis type II 216, **219**
- glycosaminoglycans, urinary excretion 222
- glycosylation, congenital disorders 78
- Gnathostoma spinigerum* **227**
- Gomori trichrome stain 216
 muscle biopsy 110, 111
- GQ1b antibodies 151, 153
- Gram stain **60, 61, 62**
- granulocytes
 basophilic 41
 in CSF 40
 do not occur in normal CSF 41
 eosinophilic 41–42
 neutrophilic 41–42
- group analysis of CSF 51
- growth hormone, serum analysis 202
- GT1b antibodies 153
- Guillain–Barré polyradiculitis 241
- Guillain–Barré syndrome 11, 147–151
 suspected 192
- H**
- Haemophilus influenzae
 in bacterial meningitis 117
 rapid antigen testing 63
- Hashimoto's encephalopathy 198

- Hashimoto's thyroiditis 78
- heart surgery, neurological damage 182
- heart-type fatty-acid-binding protein (h-FABP), in Lewy body dementia 170
- heavy metal intoxication 191
- Heidelberger-Kendall curve 17, 18, 21
- helminthic central nervous system infections **227**
- helminths **228**
- hematoidin crystals 40, 41
- hematopoietic cells 40
- hematoxylin-eosin stain 110, 111, 112
- hemoglobin, glycosylated (HbA1c) 77
- hemorrhage
- possible complication of lumbar puncture 33
 - vs contamination with blood 39
- hemorrhagic encephalitis 124, 182
- hemosiderophage, in CSF 40
- hepatitis virus (HCV), associated vasculitis 156
- hereditary motor and sensory neuropathy (HMSN1) *see* Charcot-Marie-Tooth disease
- herpes simplex virus (HSV) 123–124
- culture 64
 - encephalitis 239, 241, 242
 - immunodetection methods 55
 - PCR detection 65, 67
- herpes zoster infection 54
- high-density lipoproteins (HDL) 79
- highly active antiretroviral therapy, introduction 126, 128
- hippocampal cells, membrane staining **94**
- HIV 126–128
- chronic inflammatory demyelinating polyneuropathy (CIDP) 190
 - detection by PCR 65, 66
 - leading to Guillain-Barré syndrome 151
 - neurological complications 126–127
 - oligoclonal IgG 239
- HIV antibodies, detection 127
- HIV encephalopathy 127, 239
- opportunistic infections 231, 243
- homocysteine 80
- homocystinuria 180
- horseradish peroxidase, as marker enzyme 21
- HSV *see* herpes simplex virus
- human chorionic gonadotropin beta subunit 201
- Human Genome Project 99
- human growth hormone, contaminated 174
- human immunodeficiency virus *see* HIV
- humoral immune response
- clinical interpretation 243
 - detection 46, 60, 68
 - in Guillain-Barré syndrome 151
 - in multifocal motor neuropathy 152
 - in multiple sclerosis 138, 139, 140, 141
 - in neurosyphilis 133
 - in paraneoplastic conditions 160
 - in parasitic diseases 229, 230, 231
 - and polyspecific immune response 244
 - in viral infections 124, 125, 126, 127
- huntingtin gene 100, 101
- Huntington's disease 100, 103
- Hurst's disease 141
- hydatid disease 41
- hydrocephalus
- normal-pressure 34
 - obstructive 194
- L-2-hydroxyglutaric aciduria 224
- hyperbolic functions 7, 9, 10, 47, 48, 238, 250
- hyperlactacidemia 212
- hypervitaminosis 83
- hypnotics, overdose 83
- hypophyseal adenoma 202
- hypovitaminosis *see* vitamins, deficiencies
- hypoxia 12–13
- cerebral 185
 - lactate levels 58
-
- idiopathic intracranial hypertension *see* pseudotumor cerebri
- IgA
- CSF/serum quotient diagrams 48
 - valency 18
- IgG
- CSF/serum quotient diagrams 48
 - CSF/serum quotients 8
 - evaluation methods for reference range 47
 - intrathecal fraction 53
 - intrathecal synthesis 23
 - linear index 47
 - separation by isoelectric focusing 25
 - valency 18
 - see also* oligoclonal IgG
- IgG index, not suitable for statistics in CSF analysis 53
- IgIF 49–51
- IgLoc 49
- IgM
- CSF/serum quotient diagrams 48
 - rheumatoid factors 157
 - valency 18
- immune complex *see* antigen-antibody complex
- immune neuropathy, autoantibodies **87**
- immune response, polyspecific 240–244
- immune vasculitis, autoantibodies **86**
- immune-mediated central nervous system disorders, autoantibodies **87**
- immunoassays 21–23
- immunoblot techniques
- in autoantibody detection 87
 - for paraneoplastic antibodies 96
- immunochemical nephelometry 250
- immunochemistry 17–23
- immunocompromised patients *see* immunosuppressed patients
- immunocytochemistry 38
- in primary brain tumors 201
- immunocytology 35, 36
- immunodeficiency *see* immunosuppressed patients
- immunodetection methods, relative sensitivity 55
- immunodiffusion 46
- immunoelectrophoresis 24
- immunofixation 26
- immunofluorescence test, for ANCA 89–90
- immunoglobulins
- amounts synthesized 51
 - analysis 46–47
 - heavy and light chains 46
 - nomenclature 46
 - quantitative analytical methods 46–47
 - reference ranges 254, **257**
 - response type 238–239
 - see also* IgA; IgG; IgM
- immunohistochemical staining, of muscle biopsy 110
- immunohistochemistry, analytical function 29
- immunological tests, for mycobacterial antigen detection 121
- immunoperoxidase 38
- immunoprecipitation, in autoantibody detection 88
- immunoreactivity, in MS patients 139
- immunostaining 96
- immunosuppressed patients
- aspergillosis 130
 - autoimmune reactions 126
 - bacterial meningitis 118
 - candidiasis 129
 - CMV infections 126
 - cryptococcosis 128
 - opportunistic infections 126, 127
 - polyneuroradiculitis 190
 - primary central nervous system lymphomas 205
 - progressive multifocal leukoencephalopathy 136
 - toxoplasmosis 128
- inclusion body myositis 109, 146, **150**
- India ink stain **60**, 61, 129
- indirect immunofluorescence test (IFT) 87
- inflammation
- accompanying tumor cells 201
 - CSF signs 41
 - diagnosis 86
 - markers 73–75
 - muscle biopsy signs 109
 - see also* systemic inflammation
- inflammatory disorders, non-pathogen-related 138–163
- inflammatory myopathies, clinical symptoms **146**
- information quality, interlaboratory CSF survey 251
- informed consent 31, 100
- inheritance, polygenic 104
- inoculation meningitis 33
- Instand e.V. 249
- intercellular junctions, blood-brain barrier 5
- interferons
- autoantibodies 145
 - neutralizing antibodies 140–141
- interlaboratory CSF survey 251–253
- interleukins
- IL-6 **73**, **257**
 - IL-8 73
 - IL-12 145, 163
- intermediate-density lipoproteins (IDL) 79
- internal quality control 249
- CSF proteins 250–253
- interpretation, of CSF reports 246–248
- intoxication
- acute 83
 - coma 179
- intracellular adhesion molecules (ICAM) 197

- intracerebral hemorrhage 182–183
lactate levels 58
- intracranial pressure
continuous measurement 34
elevated 30, 33, 181, 182
increased, *see also* pseudotumor cerebri
- intrathecal antibodies *see* intrathecal immunoglobulins
- intrathecal chemotherapy, reaction to 195
- intrathecal immunoglobulins
fraction 49–51
in HSV infection 124
interpretation 54, 195
in lymphoma 206
in multiple sclerosis 138–139, 140
in neuroborreliosis 132, **133**
in paraneoplastic conditions 96
quantification 49, 243
synthesis 23, 46, 47, 96, 97, 238, 244
- intrathecal *Treponema pallidum* antibody (ITPA) index 134
- introns 99
- ion channels, antibody responses 160, **161**
- ischemic cerebral infarction *see* cerebral infarction
- ISO 15 189 249
- isoelectric focusing
in agarose gel 27, 28
of carbohydrate-deficient transferrin (CDT) 77–78
in diagnosis of multiple sclerosis 139
methods 23, 24–25
for oligoclonal IgG 46, 53, 139, 239, 252
in polyacrylamide gel 26, 27
- isoelectric point (pI) 23, 24–25
- isolated angiitis, of the central nervous system 180
- isolated facial paralysis 123, 124
- isotype switch 46, 51, 243
- isotypes, nomenclature 46
- J**
- Jamestown Canyon virus (JCV) 65, 67, 68, 136
- Jansky–Bielschowsky disease 216
- Japanese encephalitis virus serocomplex 125, 126
- K**
- Kayser–Fleischer rings 224
- kinky hair syndrome *see* Menkes' disease
- Kinyoun stain **60**
- Klebsiella*, in shunt-associated ventriculitis 122
- Krabbe's disease 216, **219**, 222
- Kufs' disease 216
- L**
- laboratory accreditation 249
- laboratory medicine, quality assessment 249
- lactate
age-dependent reference ranges **51**, 52
determination methods 57
- effect 57
elevated levels 41, 204, 212
important parameter 245
in inflammatory disease or tumor **57**
interlaboratory CSF survey 253
inverse relationship with glucose 56
L- and D-isomers 56
in leptomeningeal spread 204
in lumbar CSF 58
as marker of infection 56, 58
metabolism 56–57
in primary brain tumour 201
serial measurement 195
in subarachnoid hemorrhage 58
- lactate dehydrogenase (LDH)
frequently elevated in germinoma 201
in lactate determination 57
- lactic acidosis 56, 212
- Lagochilascaris minor* **228**
- Lambert–Eaton myasthenic syndrome 91, 145
- latex agglutination test 63, 74–75, 118, 129, 130, 134, 227, 229
- latex particles, antibody-coated 21, 61
- lead
polyneuropathy 191
reference values **192**
- Leber's hereditary optic neuropathy 215, 216
- Leigh syndrome 212, 216
- leptomeningeal proteins 11
- leptomeningeal spread
accompanied by inflammatory reaction 203
diagnosis 202–203
from carcinoma or lymphoma 198
importance in CSF analysis 202
lactate levels 204
malignant 200
- leptospirosis meningitis 117
- leukemia
central nervous system involvement 11
leptomeningeal metastasis 205
- leukodystrophies, metachromatic 108
- leukodystrophy/leukoencephalopathy, in organic aciduria 224
- Lewy bodies 171
- Lewy body dementia 69, 70, 170–171
- Lieberman method 75
- light scattering methods, for total protein determination 19–20, 45
- limb girdle muscular dystrophy 109
genetic heterogeneity 104
- limbic encephalitis 160, 198
- limulus amoebocyte lysate test 118
- linear and nonlinear evaluation methods 47
- linkage analysis 99
- lipids, reference ranges **254**, **258**
- lipoprotein fractions 79
- lipoprotein(a), serum analysis 79–80
- liquid chromatography–mass spectrometry (LC/MS/MS technique) 81
- Listeria*, in bacterial meningitis 41, 117
- Listeria monocytogenes*, in chronic meningitis 119
- lithium, therapeutic drug monitoring 81
- longitudinally extensive transverse myelitis (LETM) 157
- loss-of-function mutation 99
- low-density lipoproteins (LDL) 79
- lower motoneuron diseases 109
- lumbar CSF, lactate levels 58
- lumbar measurement of cerebrospinal pressure 34–35
- lumbar puncture
complications 32–33
contraindications 30–31, 117, 119
in diagnosis of bacterial meningitis 117
follow-up 119
indications 30
informed consent 31
intracranial pressure detection 194
postpuncture management 32
procedure 31–32
puncture site 32
sterility 59
therapeutic 30
traumatic 183–184
for tumor cell detection 203
with a ventricular shunt system 122
- lumboperitoneal shunt 194–195
- luminol 22
- lung cancer
intrathecal tumor markers 204
meningeal involvement 202
- lupus anticoagulant 90, 157
- lupus erythematosus 96
see also systemic lupus erythematosus
- Lyme disease *see* borreliosis; neuroborreliosis
- lymphatic filariasis **228**
- lymphocytes
nonspecific polyclonal activation 126
in normal CSF 39
transformed 42–43
- lymphomatous meningitis 205–206
- lysine, metabolism 222
- lysosomal disorders 108, 215, 216–222
- lysosomes 216
- M**
- M proteins *see* paraproteins
- macromolecules, diffusion 5
- malignant cells *see* tumor cells
- malignant melanoma
meningeal involvement 202, 203
metastases 43
- malignant tumors, eosinophilic tissue reaction 41
- mannosidosis 216, **219**
- May–Grünwald/Giemsa stain 37–38, 203
- measles virus
antibodies 139
see also MRZ reaction
subacute sclerosing panencephalitis 135
- medulloblastoma
meningeal involvement 200
tumor dissemination **201**
- melanin granules, in tumor cells **200**, 203
- MELAS 181
- membrane materials, for blotting methods 28
- meningeal carcinoma, ventricular CSF 44
- meningeal carcinomatosis 202, 245
- meningeal involvement *see* leptomeningeal involvement
- meningitis
decreased CSF glucose 56

- HIV 127
 neoplastic 205–207
 varicella zoster virus 124
 ventricular CSF 44
see also bacterial meningitis; chronic meningitis; meningococcal meningitis; tuberculous meningitis; viral meningitis
- meningococcal meningitis 117, 240
 meningoencephalitis 124, 198
 meningoradiculitis 131
 Menkes' disease 76, 224
 mental disorders *see* neuropsychiatric disorders
- mercury
 intoxication 191
 reference values **192**
- metabolic diseases, neurological symptoms **209–210**
- metabolic dysfunction, and neuropathy 190
 metachromatic leukodystrophy 191, 216, **219**, 222
- methionine 80
 microarray technology 101–103
 Mie scattering 20
 Miller–Fisher syndrome 151, 188
 mitochondria, electron microscopy 216
 mitochondrial disorders 211–216
 in adults **213**
 genetic classification **214**
 molecular genetic analysis 215
 mitochondrial DNA 100–101, 211
 mitochondrial metabolism 211
 mixed connective tissue disease (MCTD), nervous system involvement 154
 molecular clonality analysis 206, **207**
 molecular diagnosis 100–103
 molecular flow rate, in CSF 5, 6
 molecular genetic analysis
 for lysosomal diseases 222
 of mtDNA 215
 neuropathies 192
 of plasma viral load 127
- molecular weight data, pitfalls 97
 monoclonal gammopathy 91
 monoclonal gammopathy of undetermined significance (MGUS) 153
 monoclonal immunoglobulins 91
 monocytes, in normal CSF 39
 monogenic inheritance 99
 Morquio's syndrome **220**, 222
 motor end plate diseases, autoantibodies **86**
 motor neurography 152
 movement disorders 92, **106**
- MRI
 combined with venous MR angiography 194
 in Creutzfeldt–Jakob disease 175
 in diagnosis of leptomeningeal infiltration 203
 in multiple system atrophy 173
 in progressive multifocal leukoencephalopathy 136
 in Whipple's disease 137
see also neuroimaging
- MRZ antibody reaction 124, 132, 139, 141, 155, 239–240, 241
 mucopolisaccharidosis 216, **219**
 mucopolysaccharidoses 216, **219–220**, 222
 multifocal motor neuropathy 147, 152–153, 188
- multiple myeloma 91
 multiple sclerosis 138–141
 age-related changes 52
 albumin quotient 47
 antibody index calculation 54
 blood–CSF barrier dysfunction 52
 early diagnosis 140
 genetic factors 104
 immunoglobulin synthesis 52
 Marburg type 141
 polyspecific immune response 241
 predicted course of disease 140
 variants 141
- multiple system atrophy 173
 muscle biopsy
 biochemical analysis 110–111
 immunocytochemical analysis 104
 in inflammatory myopathies 146
 methods 109–110
 in mitochondrial disorders 215
 myopathic changes 112
 myositic changes 112, *113*
 neurogenic changes 112, *113*
 procedure 216
 routine staining 110
 typical findings 112
- muscle enzymes, in inflammatory myopathies 146
 muscle fibers, types I and II *112*
 muscle tissue, functional tests 216
 muscular dystrophies 103–104
 commercial antibodies 110, *111*
 indications for muscle biopsy 109
 musculoskeletal diseases, creatine kinase activity 80
 musculoskeletal proteins, autoantibodies 145
- MuSK, autoantibodies 145
 mutations
 direct detection 100
 pathogenic 103
- Mx proteins 141
 myasthenia gravis 144–145
 antineuronal antibody involvement 91
- mycobacteria
 culture 64
 detection in CSF 61, 65, **67**, 120–121
- Mycobacterium tuberculosis
 in chronic meningitis 119
 culture 64
 microscopic detection 61
- Mycoplasma pneumoniae
 chronic inflammatory demyelinating polyneuropathy (CIDP) 190
 and Guillain–Barré syndrome 151
- mycosis *see* fungal infections
- myelin basic protein (MBP) 139
 myelin oligodendrocyte glycoprotein antibodies, in multiple sclerosis 140
 myelin-associated glycoprotein (MAG) 153
 antibodies 188
 myelitis 123, 124
 myeloblasts, in CSF 40
 myelopathy, HIV 127
 myoadenylate deaminase (MADA), staining for 110
 myocardial disease, creatine kinase activity 80
 myopathies
 acquired 109
 congenital 109
 HIV 127
 with known gene defects **106–107**
 mitochondrial 112, 212
- myositis 109
 beta-amyloid 147
 autoantibodies 146, **147**
 obligatory diagnostic tests 147
 myotonic dystrophy (Steinert's disease) 103

N

- Naegleria fowleri* **226**
- Neels method 75
 Neisseria meningitidis
 lactate production 58
 in meningitis 117
 microscopic detection **62**
 rapid antigen testing **61**, 63, 118
- nematodes **227**
- neonatal adrenoleukodystrophy 223
 neoplasia *see* individual cancers; paraproteins
- nephelometry 19–21
 automated 46–47
 false low values 21
 particle-enhanced 21
 for total protein determination 45
- nerve biopsy
 in chronic inflammatory demyelinating polyneuropathy 152
 indications 108
 methods 108–109
 in neuropathy 193
 in paraproteinemic polyneuropathy 153
 sural nerve 109, 152
- nervous system, chronic infections 135–137
- Neubauer counting chamber 36
 neuralgia, postzoster 124
 neuroborreliosis 130–132
 antibody index 68
 characteristic data pattern 241
 chronic vs acute 240
 cytology 42, 43
 immunodetection methods 55
 PCR detection of microbial DNA 67
 time course **49**, 50
- neurodegenerative diseases 103
 with known gene defects **105**
- neurofibrillary tangles 69, 166, 169
 neurofibromatosis 103
 neurogenetics 99–107
 neuroimaging
 in Alzheimer's disease 166
 in Creutzfeldt–Jakob disease 175
 in frontotemporal lobar degeneration 172
 in Lewy body dementia 171
 in progressive multifocal leukoencephalopathy 136
 in toxoplasmosis 128
 in viral infections 124
 in Whipple's disease 137
see also MRI; PET; SPECT
- neuroleptics, therapeutic drug monitoring 81
- neurological disorders
 blood analysis 246
 genetic heterogeneity 104
 genomic classification 99

- hereditary 103
 increased CSF protein concentration 9
 with known gene defects **105**
 monogenic 103–104
 nosologic classification 86
 polygenic or multifactorial 104
 neuromuscular diseases, muscle biopsy 109
 neuromuscular transmission disorders 144
 neuromyelitis optica 141
 neuromyelitis optica spectrum disorders (NMO-SD) 157
 neuromyotonia 145–146, 160
 neuron-specific enolase (NSE)
 analysis 80
 brain–blood diffusion 12–13
 in cerebral hypoxia 185
 in CSF 71
 as epileptic seizure marker 198–199
 as neuronal destruction marker 182, 201, 245
 site of synthesis 11
 as tumor marker 204
 neuronal ceroid lipofuscinosis (NCL) 216, **220–221**, 222
 neuronal destruction, markers 69–71, 182, 201, 245
 neuronal excitability disorders **107**
 neuropathies
 HIV 127
 immune-mediated 147–159, 188
 infectious agents 190
 with known gene defects **106**
 and metabolic dysfunction 190
 molecular genetic analysis 192
 monogenic 103
 paraneoplastic etiology 190
 and porphyria 191
 and Refsum's disease 191
 tomaculous 100
 toxic 191
 vasculitic 108
 neuropathy, ataxia, andretinitis pigmentosa (NARP) 216
 neuropsychiatric disorders 176–178
 basic laboratory tests **176**
 in central nervous system SLE 157–158
 drug-induced 176
 post-streptococcal 92
 specific laboratory diagnosis **177**
 stepwise diagnosis 158–159
 vasculitis-associated 154
 neurosarcoidosis 141–142
 see also *Trypanema pallidum*
 neurosyphilis 133–135, 241
 antibody index 68
 immunological diagnosis **135**
 PCR detection of microbial DNA 67
 neurotuberculosis 240
 neutralizing antibodies, in multiple sclerosis 140–141
 neutrophilic granulocytes *see* granulocytes, neutrophilic
 new variant Creutzfeldt–Jakob disease *see* Creutzfeldt–Jakob disease
 newborns
 blood–brain barrier 9
 CSF cell counts 39
 meningitis 117
 Niemann–Pick cells 222
 Niemann–Pick disease 216, **221**, 222
 non-Hodgkin lymphoma 140, 155, 205, 238, 244
 non-neuronal antibodies 97
 nondegenerative movement disorders, with known gene defects **106**
 normoblasts, in CSF 40
 northern blot 28
 nosocomial infections **61**, 117, 123, 130
 NSE *see* neuron-specific enolase (NSE)
 nucleic acid amplification techniques, for pathogen identification 65–68
 nucleic-acid-sequence-based amplification (NASBA) 66
- O**
- oculopharyngeal muscular dystrophy 109
 oil red O stain, muscle biopsy 110, 111
 oligoclonal IgG
 in demyelinating disease 141
 detection 28, 53
 interlaboratory CSF survey 252
 in multiple sclerosis 139
 synthesis 239
 oligosaccharidoses 216
 olivopontocerebellar atrophy *see* multiple system atrophy
 Ommaya reservoir 30, 194
Onchocerca volvulus **228**
 onconeural central nervous system antigens 160
 opportunistic infections
 in HIV-positive patients 231, 239, **243**
 in immunosuppressed patients 126, 127
 of the nervous system 128–130
 PCR detection 67
Toxoplasma gondii 230, 239, **243**
 optic neuritis 140, 157
 oral glucose tolerance test (oGTT) 77
 organic aciduria, leukodystrophy/leukoencephalopathy 224
 orpinealoblastoma, risk of meningeal involvement 200
 ovarian teratoma 160
 oxalate, in chemiluminescence assay 22
- P**
- paired analysis 238
 palatal myoclonus 144
 pANCA *see* perinuclear ANCA
 PANDAS 92
 Pandy's test 45
 panencephalitis *see* progressive rubella panencephalitis; subacute sclerosing panencephalitis (SSPE)
 Pappenheim's stain 184
Paragonimus spp. **228**
 paraneoplasia, pitfalls 93
 paraneoplastic antibodies 93, **94**, 96, **161**
 paraneoplastic antigens, recombinant 97
 paraneoplastic cerebellar degeneration (PCD) 163
 paraneoplastic conditions
 clinical–immunological correlations 163
 intrathecal antibody synthesis 96
 Lambert–Eaton myasthenic syndrome (LEMS) 145
 myasthenia gravis 144
 neurological syndromes 93, 159–163
 neuromyotonia 145–146
 stiff person syndrome 143
 paraneoplastic encephalomyelitis/subacute sensory neuronopathy (PEM/SSN) syndrome 163
 paraproteinemic polyneuropathy 147, 153, **154**
 paraproteins 24, 91, 188
 parasites, culture 64
 parasitic nucleic acids, detection in CSF **67**
 parasitic worm infestations 41
see also tropical diseases
 parasitoses, relevance of CSF analysis 231
 Parkinson's disease
 genetic factors 104
 Lewy bodies 171
 and Lewy body dementia 170
 and multiple system atrophy 173
 possible antineuronal antibody involvement 91
 pathogen detection
 in brain abscess 121–122
 in cryoglobulinemic vasculitis 156
 in Guillain–Barré syndrome 151
 importance in parasitology 226
 microscopic techniques 60–63
 of mycobacteria 120–121
 in neuroborreliosis 132
 nucleic acid amplification techniques 65–68
 polyarteritis nodosa 156
 in primary and secondary syphilis 134
 in subacute sclerosing panencephalitis 135
 pathogens
 diagnosis 59–68
 propagation in culture 63–64
 patient, informed consent 31, 100
 patient information 100
 penetrance 100
 perinuclear ANCA (pANCA) 90, 156
 periodic acid–Schiff stain (PAS) 38, 60, 110
 peripheral nervous system
 classification of disorders 108
 paraneoplastic syndromes **160**
 peroxisomal diseases 222–223
 peroxisomal enzymes 222
 PET, for early diagnosis of Alzheimer's disease 166
 phagocytes, in CSF 40
 pharmacogenetic characterization 176–178
 phase prophylactics, therapeutic drug monitoring 81
 phosphofructokinase, staining for 110
 phospholipid antibodies 90–91, 157
 phosphorylase, staining for 110
 phytanic acid 223
 Pick bodies 172
 pineal germinoma, risk of meningeal involvement 200
 pinealoblastoma, tumor dissemination **201**
 pinta 133
 pipercolic acid 222, 223
 placental alkaline phosphatase (PLAP) 201
 plasma cells 42–43
 plasmacytoma 180
 plasminogen activator inhibitor I (PAI1) 179
 plausibility control 250

- PMP22 gene, point mutations 104, 192
- pneumococci
in bacterial endocarditis 120
in bacterial meningitis 57, 117
detection in CSF 61, 63, **67**
- point mutations 103
in CADASIL **107**
in Charcot–Marie–Tooth disease 104, 192
detection 100, 192
in mitochondrial syndromes **213, 214, 215**
- polyacrylamide gel 25, 26, 27
- polyendocrinopathy, autoimmune 92, 143, 144
- polymerase chain reaction (PCR) 65–66
for detection of mycobacterial DNA 121
for direct detection of microbial genomes 245
for DNA analysis 65, 101
for HSV 123
multiplex 66
nested 65
not used in diagnosis of acute bacterial meningitis 118
pitfalls 66
real-time quantitative DNA/RNA PCR 66
for varicella zoster virus 123
see also pathogen detection
- polymorphisms
ACE 76
 β -fibrinogen 179
harmless 99
prion proteins 175
prothrombin **180**
- polymyositis 109, 146, **149**
- polymyositis–scleroderma antibodies (anti-PM-Scl) 89
- polyneuropathies 187–193
etiologies 187
laboratory testing 187–188, **189–190**
serological screening 188
stepwise diagnosis 188
- polyneuropathy, lead-associated 191
- polyneuroradiculitis 190
- polyspecific immune response 240–244
- porphyria, and neuropathy 191
- positive feedback mechanism 7
- post-streptococcal central nervous system autoimmune diseases 92
- postlumbar puncture syndrome 32–33
- prealbumin *see* transthyretin
- precentrifugation 37
- precipitation methods 18–19
- predilection sites 103
- presenilin genes 166
- primary angiitis of the central nervous system (PACNS) 154
- primary central nervous system lymphomas (PCNSL) 205, **206**
- primary cerebral lymphoma, brain biopsy 108
- prion proteins 71, **107**, 108, 174, 175
- pristanic acid 223
- procalcitonin (PCT) 74
- proerythroblasts *see* pronormoblasts
- progressive multifocal leukoencephalopathy 136
- progressive rubella panencephalitis 136
- progressive supranuclear gaze palsy 173
- prolactin
as marker of epileptic seizures 197
serum analysis 202
- promyelocytes, in CSF 40
- pronormoblasts, in CSF 40
- protein–protein interactions 18
- proteins
diffusion into CSF space 6
kinetics between blood and CSF **10**
see also cerebrospinal fluid (CSF) proteins; total protein
- proteomic signature analysis, for trypanosomiasis 229
- protozoal central nervous system infections **226–227**
- Prussian blue reaction 184
- Pseudomonas* spp.
in bacterial meningitis 117
in shunt-associated ventriculitis 122
- pseudotumor cerebri 34, 194
- psychiatric disorders *see* neuropsychiatric disorders
- psychopharmaceuticals
side effects 178
therapeutic ranges **82**
- Purkinje cells
anatomy 93
cytoplasmic staining 93, **94, 95**
gliadin antibody reactivity 92, 93
nuclear staining **94, 95**
Yo-positive 162
- pyridoxine *see* vitamin B₆
- pyrogallol red–molybdate 45
- pyruvate, increased plasma levels 212
- pyruvate dehydrogenase (PDH), deficiency 212
- Q**
- Q_{Alb} *see* albumin quotient
- Q_g/Q_{Alb} **10**
- Q_{Lim} , calculation 49
- quality assessment, in the CSF laboratory 249–253
- Quincke, Heinrich I. 30
- Quincke spinal needle 31, 33
- quotient diagrams 48–51, 195
evaluation 238
group statistics 51
typical disease-related patterns 238
- R**
- Radermecker complexes 136
- radial immunodiffusion 18, 19
- radiculitis 123, 124
- radioimmunoassay 21
- radioreceptor assay (RRA) 87
- ragged red fibers 111, 216
- rapid antigen tests 61–63
- Rayleigh scattering 19, 20
- Rayleigh–Debye scattering 19, 20
- reaction equilibrium, in immune complex formation 17
- recombinant antigens 25, 89, 96, 97, 130, 132, 162
- recoverin binding retinopathy 91
- reference ranges
age-related 9, 45–46
of analytes in CSF and serum 254–260
for CSF proteins 45
establishment of 7, 8
- Refsum's disease
age of onset 223
and neuropathy 191
- reibergsgrams *see* quotient diagrams
- relative sensitivities 55
- retinitis, CMV-induced 126
- retinol *see* vitamin A
- retinol-binding protein 8
- reverse transcriptase PCR (RT-PCR) 66
- rheumatoid arthritis, nervous system involvement 154
- rhinorrhea 195–196
- rhizomelic chondrodysplasia 223
- ribosomal P protein, autoantibodies 157
- rickettsia, skin biopsy 118
- Rickham reservoir 30
- RNA viruses, detection by RNA PCR 66
- rocket electrophoresis 18–19, 24
- rubella virus
antibodies 139
see also MRZ reaction
progressive rubella panencephalitis 136
- Russian spring-summer encephalitis (RSSE) virus 124
- ruthenium complexes, in chemiluminescence assay 22
- Ryan radioactive method 75
- ryanodine receptor (RyR) antibodies 87, 145
- S**
- S 100 proteins
in CSF 71
neuronal destruction markers 80, 201
- S 100A 71
- S 100B
in cerebral hypoxia 185
in Creutzfeldt–Jakob disease 71, **168, 169**, 174
in CSF **12, 71**
in frontotemporal lobar degeneration 172
neuronal destruction marker 71, **168, 182**, 245, 246
reference ranges **257**
synthesis site 11
in temporal lobe epilepsy 199
- Sanfilippo's syndrome **220, 222**
- Santavuori's disease 216
- sarcoidosis
multisystem disorder 141
screening test 190
- Sayk sedimentation chamber 37
- Schellong test 173
- Schindler's disease 216, **221**
- Schistosoma* spp. **228**
- schizophrenia
CSF findings 178
possible antineuronal antibody involvement 91
- scleroderma, nervous system involvement 154
- sea-blue histiocytes **221, 222**
- sedimentation chamber procedure 37
- senile plaques 166
- sensory irritation, possible complication of lumbar puncture 33

- sensory neuronopathy
 paraneoplastic etiology 190
 see also neuropathies
 septic shock 119
 septic sinus thrombosis 119
 serum
 analysis 73–85
 electrophoresis 24
 immunoelectrophoresis 26
 osmolarity, monitoring 179
 reference samples 251
 serum proteins
 concentration 9
 in CSF 9–11
 early detection in lumbar CSF 11
 molecular size 9
 reference ranges in CSF and serum 254, 256
 Sharp's syndrome, nervous system involvement 154
 shell vial culture 64
 shunts
 foreign body reaction 41
 ventriculitis 122
 Shy-Drager syndrome *see* multiple system atrophy
 SIADH *see* symptom of inappropriate anti-diuretic hormone
 sialic acid storage disease 216, 221
 sialidosis 216
 siderophages 195
 signal transduction 70
 signet-ring cells
 in CSF 40
 in leptomeningeal metastasis 203, 204
 silver staining 28
 Silverstein method 75
 Sjögren's syndrome
 antibodies 96
 antigens 89
 aquaporin-4, antibodies 157
 nervous system involvement 154
 skeletal muscle proteins, antibodies 87
 skin biopsy
 CADASIL 107, 180, 181
 Fabry's disease 217
 for fibroblast culture 216, 222
 neuroborreliosis 177
 neuronal ceroid lipofuscinosis 222
 rickettsia 118
 SLE *see* systemic lupus erythematosus
 sodium dodecyl sulfonate (SDS) gel electrophoresis 24
 software, used in CSF reporting 246
 soluble interleukin-2 receptor (sCD25) 74, 76
 somatic hypermutations, in multiple sclerosis 139
 somatosensory evoked potentials, in cerebral hypoxia 185
 Southern blot 28, 192
 SOX1 145, 162
 see also anti-SOX1
 space-occupying lesions
 in brain parenchyma 202
 increased intracranial pressure 34, 194
 spinal cord compression 33
 ventricular drainage 194
 spastic spinal paralysis 103
 SPECT, in frontotemporal lobar degeneration 172
 sphingolipidoses 216
 Spielmeier-Vogt disease 216
 spinal block, complete 11
 spinal cord compression 33
 spinal epidural abscess 122
 spinal stenosis 11
 spinocerebellar ataxia 103
 spinocerebellar degeneration 85
 spongiform leukodystrophy 224
 Spottle needle 31, 33
 sprue 92
 SSPE *see* subacute sclerosing panencephalitis
 staining techniques
 for CSF sediments 37
 differential 60
 stains, for microscopical detection of pathogens 60
 staphylococci
 Gram staining 61, 62
 in meningitis 117
 microscopic detection 61
 nucleic acid detection 67
 in shunt-associated ventriculitis 122
Staphylococcus aureus, in bacterial endocarditis 120
 Steele-Richardson-Olszewski syndrome *see* progressive supranuclear gaze paresis
 stepwise diagnosis
 of neuropsychiatric manifestations 158–159
 in polyneuropathies 188
 in systemic vasculitis 158, 159
 stereoselective derivatization 81
 sterol 27-hydroxylase deficiency 223
 stiff person syndrome 92, 143, 160, 161, 163
 streptococci
 in bacterial meningitis 117
 rapid antigen testing 63
Streptococcus pneumoniae, rapid antigen testing 63
 striatonigral degeneration *see* multiple system atrophy
 stroke
 common cause of death 179
 prevention 181
 see also cerebral infarction; intracerebral hemorrhage; subarachnoid hemorrhage
Strongyloides stercoralis 228
 subacute sclerosing panencephalitis (SSPE) 135, 239, 241
 subarachnoid hemorrhage 40, 41, 58, 183–185
 lactate levels 58
 subarachnoid space
 brain abscess 121
 CSF flow 3, 4
 diffusion into 5, 6, 7
 filariform larvae 228
 puncture 31
 rostrocaudal concentration gradient 6, 8, 11, 254
 secondary brain tumors 202
 subcortical arteriosclerotic encephalopathy 173–174
 suboccipital puncture 30
 substrates, reference values 255
 succinate dehydrogenase (SDH), specific staining procedures 110
 Sudan black 38
 Sudan red 38
 sugars
 blood-brain barrier 5
 see also individual sugars
 suicide attempts 83
 sulfate-3-glucuronyl paragloboside (SGPG) 153
 sulfate-3-glucuronyl-neolactose paragloboside (SGLPG) 153
 suprasellar germinoma 200
 sural nerve, biopsy 109, 152
 Sydenham's chorea 92
 symptom of inappropriate anti-diuretic hormone (SIADH) 119
 syphilis, central nervous system complications *see* neurosyphilis
 systemic diseases, diagnosis by nerve biopsy 108
 systemic inflammation
 autoantibodies 86
 in cases of brain abscess 121
 in nonpurulent bacterial meningitis 119
 signs 86, 121
 TNF α 74
 systemic inflammatory response syndrome (SIRS) 73
 systemic lupus erythematosus (SLE)
 aquaporin-4, antibodies 157
 clinical-immunological correlations 157–158
 nervous system involvement 154–155
 systemic necrotizing vasculitis 156
 systemic vasculitis 154–156
 ANCA 190
 immune complex-mediated forms 156
 laboratory findings 156, 158, 180, 194
 neurological complications 155
 stepwise approach to diagnosis 158, 159

T

- T cells *see* lymphocytes
 tabes dorsalis 134
Taenia solium 227
 Takayasu's syndrome 156, 180
 tau protein
 in Alzheimer's disease 166, 170, 245
 in Creutzfeldt-Jakob disease 174, 175
 in dementia and depression 69
 gene 172
 in Lewy body dementia 170
 site of synthesis 11
 in subcortical arteriosclerotic encephalopathy 174
 telencephalin 197–198
 temporal arteritis 180
 temporal lobe epilepsy 144
 thallium
 intoxication 192
 reference values 192
 therapeutic drug monitoring 81, 176–177
 thiamine *see* vitamin B₁
 thin-layer chromatography (TLC), in autoantibody detection 88
 three-glass test 183–184
 throat swab 118
 thrombocytopenia 180
 thrombophilic factors 179

- thymoma-associated myasthenia gravis 144, 145
- thyroid function
 markers 78
 measuring 190
- thyroid hormones 78
- tic disorders 92
- tick-borne encephalitis 124
- tinnitus, pulsatile 194
- tissue factor pathway inhibitor (TFPI) 179
- titin antibodies 87, 145
- tocopherol *see* vitamin E
- tonic-clonic seizures *see* epileptic seizures
- total protein analysis
 interlaboratory CSF survey 252
 nephelometric methods 19
 in primary brain tumour 201
 quantification 44–45
 turbidimetric determination methods 45
- Tourette's syndrome 92
- Tourtellotte formula 47
- toxicological laboratory diagnosis 83
- Toxocara canis/cati* 227
- Toxoplasma*, opportunistic infection 230, 239, 243
- Toxoplasma* abscesses, suspected 122
- Toxoplasma gondii*
 central nervous system infection 230
 parasitic behavior 128
 PCR detection 65
- toxoplasmosis
 in Africa 231
 cerebral 128
 diagnosis 68
 HIV 243
- tranquilizers, overdose 83
- transferrin 77–78
 asialo form 11
- transthyretin 8, 11
- trematodes 228
- Treponema carateum* 133
- Treponema pallidum*
 in chronic meningitis 119
 cross-reactivity 55
 hemagglutination (TPHA) 134
 natural immunity 133
 particle agglutination (TP-PA) 134
 serological tests 134
- Treponema pertenuis* 133
- Trichinella spiralis* 227
- triglycerides
 in lipoproteins 79
 serum analysis 78–79
- Trinder reaction 79
- trinucleotide expansions 100, 103
- trinucleotide repeat sequences, unstable 103
- Tropheryma whipplei* 60, 137
 PCR detection 66, 68
- tropical diseases 226–232
- Truant auramine–rhodamine stain 60
- Trypanosoma brucei gambiense/rhodesiense* 226
- Trypanosoma cruzi* 227
- trypanosomiasis 229
- tryptophan load test 85
- TSH *see* thyroid-stimulating hormone
- tuberculoma, suspected 122
- tuberculostearic acid determination 121, 122
- tuberculous meningitis 120–121
 cytology 41
 geographic differences 230–231
 lactate levels 58
- tuberculous spondylitis 120
- tumor cells
 diagnosis in CSF 43
 morphology 203
- tumor markers
 in CSF analysis flow chart 237
 determination 200, 244
 for intracranial tumors 201, 202
 intrathecal 203, 204, 205
 paraneoplastic antibodies 96
 reporting 235
 S-100 protein 71
- tumor necrosis factor (TNF α) 73–74
- turbidimetric methods 19–21, 45, 46
- U**
- urinalysis
 drug detection tests 176
 in lysosomal diseases 222
 metabolite analysis 215
 in suspected SLE 158
- V**
- variant Creutzfeldt–Jakob disease *see* Creutzfeldt–Jakob disease
- varicella virus, antibodies, *see also* MRZ reaction
- varicella zoster virus (VZV)
 antibodies 139
 immunodetection methods 55
 neurological complications 124
 PCR detection 65, 67
 polyneuroradiculitis 190
- vasculitis
 allergic 190
 immune complex-mediated 180
 and multiplex neuropathies 190
 rare cause of cerebral infarction 179–180
 rare cause of intracerebral hemorrhage 182
 varicella zoster virus 124
- Venereal Disease Research Laboratory (VDRL) test 134
- ventricular catheters
 complications 35
 CSF collection 32
 CSF pressure measurement 35
 use 30
- ventricular CSF
 collection 30, 32
 cytology 195
 lactate levels 58
 special features 44
- ventricular drainage, external/internal 194–195
- ventricular puncture 30
- ventricular tamponade 194
- ventriculitis 122–123
- ventriculoatrial/ventriculoperitoneal shunts 194–195
- very low-density lipoproteins (VLDL) 79
- vimentin 201
- viral antibodies, detection 124
- viral culture 64
- viral encephalitis 123
- viral infections
 antibody index 68
 of the central nervous system 242
 immunodetection methods 55
 of the nervous system 123–128
- viral meningitis 41, 42, 123
 lactate concentrations 58
- viral nucleic acids, detection in CSF 66–67
- viruses, valency 18
- vitamin A 83
- vitamin B₁ 83–84
- vitamin B₆ 84–85
- vitamin B₁₂ 76–77
- vitamin C 12
- vitamin E 85
- vitamins
 blood–brain barrier 5
 deficiencies 80, 83, 85, 190
 determination 83
 reference ranges 254, 258
see also hypervitaminosis
- voltage-gated calcium channels (VGCC), antibodies 145
- voltage-gated potassium channels (VGKC), antibodies 146
- VZV *see* varicella zoster virus (VZV)
- W**
- Waldenström's macroglobulinemia 91
- West Nile Virus (WNV) 125–126
- western blot
 for antibody detection 68
 for *Borrelia* antigen detection 26
 comparative sensitivity 55
 for oligoclonal IgG 53
 procedure 28
- Whipple's disease 38, 60, 137
- Wilson's disease 76, 103, 224
- Wood, Alexander 30
- X**
- X-linked adrenoleukodystrophy (ALD) 223
- xanthochromia 39, 184
- Y**
- yaws 133
- yellow fever vaccination, cross-reactivity 126
- Z**
- Zellweger's syndrome 222–223
- Ziehl–Neelsen stain 60, 61, 120
- zoonosis of the central nervous system 41
see also parasitoses; tropical diseases
- zoster ganglionitis 239, 242
see also facial nerve palsy